Uses of Natriuretic Peptide Constructs
AssigneePalatin Technologies, Inc.
InventorsMargarita Bastos, Jennifer Lata, Jeffrey D. Edelson
Life of this patent
Estimating the term…
Abstract
Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or COPD, methods of prophylaxis and treatment of airway diseases and pharmaceutical compositions and formulations for the prophylaxis or treatment of airway diseases.
Claims15
A method of treatment or prophylaxis of an airway disease, comprising administration of a pharmaceutically effective amount of a composition comprising a construct which binds to a natriuretic peptide receptor and comprises a plurality of amino acid residues and at least one amino acid surrogate of formula I:
- wherein:
- R and R′ are each independently H or a natural or unnatural amino acid side chain moiety or derivative of an amino acid side chain moiety;
- x is 1 or 2;
- Y is CH2 or C═O;
- W is CH2, NH or NR′″;
- Z is H or CH3;
- J is —C(═O)— unless the surrogate is at the C-terminus position of the construct, in which case J is —H, —OH, —C(═O)—OH, —C(═O)—NH2, or a C-terminus capping group;
- Q is a bond unless the surrogate is at the N-terminus position of the construct, in which case Q is —H or an amine capping group;
- R′″ is an acyl, a C1 to C17 linear or branched alkyl chain, a C2 to C19 linear or branched alkyl acyl chain, a C1 to C17 linear or branched omega amino aliphatic, or a C1 to C17 linear or branched omega amino aliphatic acyl;
- n is 0, 1 or 2;
- and
- the carbon atoms marked with an asterisk can have any stereochemical configuration;
- and
- with the at least one surrogate of formula I being covalently bonded to at least one of the plurality of amino acid residues.
Use of a construct which binds to a natriuretic peptide receptor and comprises a plurality of amino acid residues and at least one amino acid surrogate of formula I:
- wherein:
- R and R′ are each independently H or a natural or unnatural amino acid side chain moiety or derivative of an amino acid side chain moiety;
- x is 1 or 2;
- Y is CH2 or C═O;
- W is CH2, NH or NR′″;
- Z is H or CH3;
- J is —C(═O)— unless the surrogate is at the C-terminus position of the construct, in which case J is —H, —OH, —C(═O)—OH, —C(═O)—NH2, or a C-terminus capping group;
- Q is a bond unless the surrogate is at the N-terminus position of the construct, in which case Q is —H or an amine capping group;
- R′″ is an acyl, a C1 to C17 linear or branched alkyl chain, a C2 to C19 linear or branched alkyl acyl chain, a C1 to C17 linear or branched omega amino aliphatic, or a C1 to C17 linear or branched omega amino aliphatic acyl;
- n is 0, 1 or 2;
- and
- the carbon atoms marked with an asterisk can have any stereochemical configuration;
- and
- with the at least one surrogate of formula I being covalently bonded to at least one of the plurality of amino acid residues;
- in the manufacture of a medicament for the treatment or prophylaxis of an airway disease.
A pharmaceutical composition adapted for inhalation administration, comprising a dry powder formulation comprising a construct of formula IV:
- or a pharmaceutically acceptable salt of the construct of formula IV, and a pharmaceutically acceptable carrier.
A pharmaceutical composition adapted for inhalation administration utilizing a nebulizer, comprising an aqueous formulation comprising a construct of formula IV:
- or a pharmaceutically acceptable salt of the construct of formula IV.
Dependencies are inferred from the claim text.